Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4NMBW)

• Drug Name: Anti-Mesothelin CAR-T cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Gastric adenocarcinoma	2B72	Phase 1/2	[1]
Mesothelioma	2C51.2	Phase 1/2	[1]
Pancreatic cancer	2C10	Phase 1/2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM4NMBW

Molecule-Related Drug Atlas

Drug(s) Targeting Mesothelin (MSLN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CRS-207	DMXU5LZ	Gastric adenocarcinoma	2B72	Phase 2	[3]
MORAb-009	DMCXNIP	Mesothelioma	2C51.2	Phase 2	[4]
Anti-mesothelin CAR transduced PBL	DMXI03L	Cervical cancer	2C77.0	Phase 1/2	[5]
CAR-T cells targeting Mesothelin	DMMAQJ7	Cervical cancer	2C77.0	Phase 1/2	[6]
HPN536	DM86OJ0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
CAR-T cells targeting mesothelin	DMPK35H	Pancreatic cancer	2C10	Phase 1/2	[8]
TC-210	DM9S5I1	Cholangiocarcinoma	2C12.10	Phase 1/2	[9]
TC-510	DMSPG60	Breast cancer	2C60-2C65	Phase 1/2	[10]
CARTmeso/19	DMV84ZR	Pancreatic cancer	2C10	Phase 1	[11]
CART-meso-19 T cells	DMZ4I03	Pancreatic cancer	2C10	Phase 1	[12]
CRS-207	DMXU5LZ	Gastric adenocarcinoma	2B72	Phase 2	[3]
MORAb-009	DMCXNIP	Mesothelioma	2C51.2	Phase 2	[4]
Anti-mesothelin CAR transduced PBL	DMXI03L	Cervical cancer	2C77.0	Phase 1/2	[5]
CAR-T cells targeting Mesothelin	DMMAQJ7	Cervical cancer	2C77.0	Phase 1/2	[6]
HPN536	DM86OJ0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
CAR-T cells targeting mesothelin	DMPK35H	Pancreatic cancer	2C10	Phase 1/2	[8]
TC-210	DM9S5I1	Cholangiocarcinoma	2C12.10	Phase 1/2	[9]
TC-510	DMSPG60	Breast cancer	2C60-2C65	Phase 1/2	[10]
CARTmeso/19	DMV84ZR	Pancreatic cancer	2C10	Phase 1	[11]
CART-meso-19 T cells	DMZ4I03	Pancreatic cancer	2C10	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mesothelin (MSLN)	TT4RXME	MSLN_HUMAN	CAR-T-Cell-Therapy	[2]

References

• [1] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [2] ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
• [3] Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.
• [4] Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.
• [5] ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
• [6] ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
• [7] Clinical pipeline report, company report or official report of Harpoon Therapeutics.
• [8] ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• [9] Clinical pipeline report, company report or official report of TCR2 Therapeutics.
• [10] Clinical pipeline report, company report or official report of TCR2 Therapeutics
• [11] ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
• [12] ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer